Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2019-02-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma:-opportunities-and-challenges |
| _version_ | 1811209988641652736 |
|---|---|
| author | Shinichi Makita Katsuaki Imaizumi Saiko Kurosawa Kensei Tobinai |
| author_facet | Shinichi Makita Katsuaki Imaizumi Saiko Kurosawa Kensei Tobinai |
| author_sort | Shinichi Makita |
| collection | DOAJ |
| description | B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL. |
| first_indexed | 2024-04-12T04:49:16Z |
| format | Article |
| id | doaj.art-cc7cf8f6699b4c228c3cae9866862600 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-04-12T04:49:16Z |
| publishDate | 2019-02-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-cc7cf8f6699b4c228c3cae98668626002022-12-22T03:47:22ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982019-02-01811410.7573/dic.212567Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challengesShinichi MakitaKatsuaki Imaizumi Saiko KurosawaKensei TobinaiB-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL.https://www.drugsincontext.com/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma:-opportunities-and-challengesaxicabtagene ciloleucelB-cell non-Hodgkin lymphomaCAR-TCD19chimeric antigen receptordiffuse large B-cell lymphomalisocabtagene maraleuceltisagenlecleucel |
| spellingShingle | Shinichi Makita Katsuaki Imaizumi Saiko Kurosawa Kensei Tobinai Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges Drugs in Context axicabtagene ciloleucel B-cell non-Hodgkin lymphoma CAR-T CD19 chimeric antigen receptor diffuse large B-cell lymphoma lisocabtagene maraleucel tisagenlecleucel |
| title | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| title_full | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| title_fullStr | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| title_full_unstemmed | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| title_short | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| title_sort | chimeric antigen receptor t cell therapy for b cell non hodgkin lymphoma opportunities and challenges |
| topic | axicabtagene ciloleucel B-cell non-Hodgkin lymphoma CAR-T CD19 chimeric antigen receptor diffuse large B-cell lymphoma lisocabtagene maraleucel tisagenlecleucel |
| url | https://www.drugsincontext.com/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma:-opportunities-and-challenges |
| work_keys_str_mv | AT shinichimakita chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges AT katsuakiimaizumi chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges AT saikokurosawa chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges AT kenseitobinai chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphomaopportunitiesandchallenges |